• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

What is the Prevalence of Occult Malignancy During Hysterectomy or Myomectomy for Benign Indications?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Hysterectomy and myomectomy are common gynecologic surgeries, often done for benign conditions
  • Desai et al. (Obstet Gynecol, 2018) estimated the prevalence of occult uterine, cervical and ovarian malignancy in women undergoing hysterectomy or myomectomy for benign indications

METHODS:

  • Secondary analyses of data from American College of Surgeons National Surgical Quality Improvement Program (2014-2015)
  • Adult women undergoing hysterectomies and myomectomies without evidence of cancer were included in the analyses
  • Primary outcome was pathology-confirmed uterine, cervical and ovarian malignancy
  • Secondary outcome was that of stage of identified occult malignancies
  • Results were adjusted to account for confounders using logistic regression analysis

RESULTS:

  • 24,076 women underwent hysterectomy; 2,368 underwent myomectomy
  • For those women undergoing hysterectomy, prevalence of occult cancers were as follows
    • Uterine cancer: 1.44%
    • Cervical cancer: 0.60%
    • Ovarian cancer: 0.19%
  • The prevalence of uterine cancer varied depending on surgical procedure
    • Laparoscopic supracervical hysterectomy: 0.23%
    • Total laparoscopic or laparoscopic-assisted vaginal hysterectomy 1.89%
  • Older women were significantly more likely to have preoperatively undetected uterine malignancy when comparing women age ≥55 years vs age 40-54 years
    • Adjusted odds ratio 6.46; 95% CI, 4.96-8.41
  • Among patients undergoing myomectomy, 0.21% were found to have malignancy of the corpus uteri with no occult cervical or ovarian cancer identified
  • Staging
    • 80% of uterine cancers and 60.9% of ovarian cancers were stage I-IC neoplasms
    • 44.1% of cervical cancers were diagnosed at stage I-IB2 and 40.7% had stage ‘not otherwise specified’ (NOS)

CONCLUSION:

  • Large and diverse patient population
  • Results provide additional information regarding the potential for malignancy with intracorporeal electromechanical morcellation
  • Prevalence varied based on patient age and surgical route
    • Prolapse may be associated with lower risk of malignancy
    • Surgeons may opt for complete removal of the uterus in women who may be at higher risk for malignancy, hence the higher risk of malignancy using this approach
  • The results indicate the importance of a thorough workup for malignancy in women who are 55 years of age or older

The ‘ACOG Statement on FDA Regulation of Morcellation’ (2015) states

As a result of the continuing conversation about morcellation, obstetrician-gynecologists are better able to evaluate each individual woman’s risk of an undiagnosed sarcoma, and to counsel her to receive the right approach for her own unique medical needs.

Learn More – Primary Sources:

Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications

ACOG Statement on FDA Regulation of Morcellation

 

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does the Reduction in Power Morcellation Use Impact the Minimally Invasive Hysterectomy Rate? 
What is the Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation?
‘Opportunistic’ Salpingectomy at the Time of Hysterectomy: Risks vs Benefits
No Power Morcellators? Can We Expect More Wound Complications Due to Minilaps at Myomectomy? 

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site